Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on angiogenesis

Xin Pan, Yong Wang, Min Zhang, Wei Pan, Zhong-Tian Qi, Guang-Wen Cao

AIM: To investigate the inhibitory effects of endostatin-vascular endothelial growth inhibitor (VEGI) recombinant adenoviruses on neovascularization.

METHODS: We used recombinant adenoviruses to treat human vascular endothelial cell line ECV304, human hepatocellular carcinoma cell line HepG2, and murine fibroblast cell line L929, in order to study the chimeric gene expression in these cell lines. Chick chorioallantoic membrane (CAM) model, rabbit inflammatory corneal neovascularization (CNV) model, and liver cancer-bearing nude mice model were employed to investigate the negative biological effect of fusion molecules on neovascularization in vivo.

RESULTS: Western blot showed that the molecular weight of fusion protein was about 41kD after infection of ECV304, HepG2 and L929 cells with supernatant of AdhENDO-VEGI. The fusion protein showed a specific inhibitory effect on the proliferation of ECV304 cells, but no inhibitory effect on the growth of HepG2 and L929 cells (F=13112.13, P=0.0001). In the chick chorioallantoic membrane (CAM) assay, the expressed fusion protein significantly inhibited neovascularization. Rabbit inflammatory corneal neovascularization (CNV) induced by intrastromal sutures resulted in a uniform neovascular response. In this model, direct subconjunctival injection of AdhENDO-VEGI expressed the fusion protein in vivo and suppressed the development of CNV. Topical application of AdhENDO-VEGI led to a significant suppression of CNV (F=1413.11, P=0.0001), as compared with the control group of AdLacZ. Immunohistochemical staining showed the fusion protein dominantly expressed in corneal epithelium. Compared with the control group of AdLacZ, Immunohistochemical staining showed the adenoviruses carried the fusion gene expressed on liver cancer cell membrane. MVD decreased more significantly in treated mice (30.75±3.31%) than in AdLacZ control (50.25±8.65%) (F=17.72, P=0.0056) with an inhibition rate of 39%.

CONCLUSION: Fusion protein expressed by recombinant adenoviruses has a significant inhibitory effect on neovascularization.

Pan X, Wang Y, Zhang M, Pan W, Qi ZT, Cao GW. Effects of endostatin-vascular endothelial growth inhibitor chimeric recombinant adenoviruses on angiogenesis. World J Gastroenterol 2004; 10(10): 1409-1414

INTRODUCTION

Neovascularization plays a critical role in solid tumor growth and corneal opacification. Researches indicated that angiogenesis inhibitors were highly potent in suppressing angiogenesis which could enable the tumor mass to remain in a dormant state and inhibit the development of corneal neovascularization. Endostatin could cause G(1) cell cycle arrest in endothelial cells, inhibit endothelial cell proliferation and migration, and promote apoptosis. Vascular endothelial cell growth inhibitor (VEGI) belongs to the tumor necrosis factor superfamily. VEGI is another endothelial cell-specific gene and a potent inhibitor of endothelial cell proliferation, angiogenesis. VEGI could mediate early G(1) arrest in G(0)/G(1) endothelial cells responding to growth stimuli, and programmed death in proliferating endothelial cells. In our laboratory two recombinant proteins have been used to treat tumor-bearing nude mice, but the inhibitory effect was not satisfactory. A few groups have demonstrated that antiangiogenic gene therapy with viral vectors is a potentially useful approach for inhibiting tumor growth in mouse models. In the current study, we acquired recombinant adenoviruses carrying endostatin-vascular endothelial growth inhibitor fusion gene to investigate its inhibitory effect in vitro on endothelial cells and antiangiogenic activity in vivo on chicken chorioallantoic membrane, inflammatory corneal neovascularization (CNV) in rabbit and liver cancer in nude mice.

MATERIALS AND METHODS

Materials

AdhENDO-VEGI, and AdLacZ were prepared in our laboratory. Endostatin polyclonal antibody was a gift from Dr. Stanker (Hanover, Germany). VEGI polyclonal antibody was prepared in our laboratory. Ad5-transformed human embryo renal cell line 293, human vascular endothelial cell line ECV304, human hepatocellular carcinoma cell line HepG2, and murine fibroblast cell line L929 were purchased from the Institute of Cell Biology, Chinese Academy of Sciences. Cell culture media were obtained from GIBCO. Nine-day-old fertilized white Leghorn eggs, New Zealand white rabbits, liver cancer-bearing nude mice SMMC-LTNM, and BALB/c nude mice were purchased from the Center of Experiment Animals, Second Military Medical University (Shanghai, China). All cell lines and animals were maintained under standard conditions.

Methods

Recombinant adenovirus infectivity examination AdhENDO-
applied to the eyes once per day. Eyes were examined daily by

**Western blotting analysis**

Ad5-transformed human embryo renal cell line 293, human vascular endothelial cell line ECV304, human hepatocellular carcinoma cell line HepG2, and murine fibroblast cell line L929 were used in this assay. In a 6-well plate, 1×10⁶ cells were infected with recombinant adenoviruses at an MOI of 20 for 4 h, then the medium containing recombinant adenoviruses was replaced with 1 mL of normal medium and cells were incubated for 24 h. Cell extracts were prepared with 100 g/L sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions and electrophoresed onto nitrocellulose membrane followed by treatment with blocking buffer containing 50 g/L nonfat dry milk in TBST (20 mmol/L Tris [pH8.0], 150 mmol/L NaCl, 1 g/L Tween-20) for 1 h. The electrophoresed membranes were incubated with rabbit polyclonal antibodies against VEGI proteins, then subsequently incubated with peroxidase horseradish-conjugated anti-rabbit immunoglobulin for 1 h at 37 °C. The immune complexes were visualized with diaminobenzidine (DAB) staining.

**In vitro bioactivity of fusion gene products**

One×10⁶ cells were incubated in the 96-well plates, cells were infected with recombinant adenoviruses at an MOI of 20 for 4 h. The cell lines were ECV304, HepG2, and L929, respectively. The recombinant adenoviruses were AdhENDO-VEGI₃ and AdLacZ, respectively. The medium containing recombinant adenoviruses was replaced with 100 µL of normal medium and cells were incubated at 37 °C for an appropriate period of time. The medium containing recombinant adenoviruses was removed, murine fibroblast cell line L929 was incubated with a normal medium containing 0.5 µg/mL actinomycin D. Cell viability was determined by crystal violet vital staining. Cell viability (%) = (AdhENDO-VEGI₃ infected group A₃700nm/AdLacZ control group A₃700nm)×100. Inhibition of chick embryonic chorioallantoic membrane angiogenesis by recombinant adenoviruses A 1 cm × 1 cm window in the shell was drilled over the air sac at the end of 9-day-old eggs. Chick embryonic chorioallantoic membrane was exposed by tearing up the egg membrane with a tip. A disk of 4-5 kg, were used. Inflammatory CNV in rabbits induced by placement of intrastromal sutures resulted in a uniform neovascular response as described[20]. On the first day after saturation, four rabbits were divided into AdLacZ control group and AdhENDO-VEGI₃ group. One hundred microliters of each recombinant adenovirus at a titer of 1×10¹² TCID₅₀/L was injected into subconjunctiva. Then, gentamicin ointment was applied to the eyes once per day. Eyes were examined daily by a slit-lamp biomicroscope and a surgical microscope was used to monitor angiogenic responses to recombinant adenoviruses. The area of corneal neovascularization was determined by measuring the vessel length (L) from the limbus and the number of clock hours (C) of limbus involved[21-24]. Only the uniform contiguous band of neovascularization adjacent to the suture was measured. A formula was used to determine the area[25]:

\[ \text{Area} = \pi \times r^{2} - (r-L)^{2}, \]

where \( r = 6 \) mm (the measured radius of rabbit cornea). Rabbits were sacrificed on d 21. Rabbits’ eyes were enucleated and inflammatory cornea was fixed in 40 g/L paraformaldehyde for 24 h.

**Immunohistochemical staining of fusion protein in inflammatory cornea of rabbits**

Buffered formaldehyde fixed tissues were embedded in paraffin, 4-µm thick sections were treated with 3 mL/L H₂O₂ in methanol for 20 min, and blocked with normal rabbit serum (1:20 dilution) for 20 min at room temperature. Then, the sections were incubated with rabbit polyclonal anti-endostatin (1:50 dilution) for 1 h at room temperature, followed by incubation with biotinylated goat anti-rabbit antibody IgG for 30 min and horseradish peroxidase-conjugated streptavidin at room temperature for 30 min. After completion of conjugation reaction, the slides were stained using 3,3’-diaminobenzidine (DAB)-H₂O₂. The sections were counterstained with hematoxylin, and viewed using a light microscope.

**Treatment of liver cancer-bearing nude mice with recombinant adenoviruses**

Three SMMC-LTNM nude mice with liver cancer were sacrificed, and skin overlying the tumor was cleaned with ethanol. The tumors were resected under asceptic conditions. A suspension of tumor cells in Hank’s was made by passage of viable tumor tissues small hypodermic needles. The final concentration was adjusted to 2×10⁵ cells/mL. Female Balb/c nude mice, 3 wk of age, received injections sc into the dorsal midline in a 200 µL volume. Tumors appeared approximately 10 d after implantation. The animals were randomized into 2 groups, and each group had four mice with comparable tumor size within and among the groups. Five hundred microliters of recombinant adenoviruses AdhENDO-VEGI₃ or AdLacZ at a titer of 1×10¹⁵ TCID₅₀/L was administered 10 times by sc every other day. The mice were sacrificed 24 h after the last injection, tumors from each mouse were removed and fixed in 40 g/L neutral buffered formaldehyde. Tumor size in all groups was measured, tumor volume was determined using the formula \( \text{volume} = \pi \times (r-L)^{2} \times h / 6 \). Tumor weight, inhibition rate and expression of target gene were evaluated, respectively.

**Immunohistochemical staining of fusion protein in liver cancer of nude mice**

Tissues from liver cancer of nude mice were fixed in 40 g/L neutral buffered formaldehyde, embedded in paraffin, and sectioned into 4 µm. The sections were treated with PBS, blocked with normal rabbit serum, incubated with rabbit polyclonal anti-endostatin (1:100 dilution) overnight at 4 °C, washed with PBS, incubated with HRP-conjugated goat anti-rabbit antibody (1:500 dilution) for 1 h at 37 °C, and stained using 3,3’-diaminobenzidine (DAB)-H₂O₂, counterstained with hematoxylin, and examined by a light microscope.

**Determination of intratumor microvessel density**

Determination of microvessel density was carried out as described[26-28]. Briefly, intratumor microvessels were immunostained with rat anti-human CD34 monoclonal antibody, and visualized with a biotinylated anti-rat IgG antibody by the Strept Avidin-Biotin Complex method. The sections were examined under low power to identify most vascular areas of the tumor. Within these areas, a maximum of 3 fields at ×200 magnification was examined, and the mean values were calculated.

**Statistical analysis**

Data were expressed as mean±SD. An analysis of variance was performed with Statview 4.0 statistical analysis software, and \( P < 0.05 \) was considered statistically significant.
RESULTS

Recombinant adenovirus infectivity
The titer of amplification of these two kinds of recombinant adenoviruses was $1 \times 10^{12}$ TCID$_{50}$/L. When ECV304 cells were infected with AdLacZ at an MOI of 0.1, 20% cells showed LacZ-positive staining. If MOI was 20, 100% cells were stained blue (Figure 1). This result suggested recombinant adenoviruses had the highly efficient gene delivery.

Fusion protein expression of AdhENDO-VEGI$_{151}$ in vitro
Four kinds of cell lines infected with AdhENDO-VEGI$_{151}$ were immunoblotting stained with polyclonal antibodies against VEGI and visualized with DAB system. The results demonstrated that the fusion gene carried by AdhENDO-VEGI$_{151}$ could be in vitro expressed in all the cell lines, and the specific bands were located at about 41 ku, which was the expected size of ENDV-VEGI$_{151}$ fusion protein (Figure 2).

In vitro bioactivity of fusion gene on different cell lines
Human vascular endothelial cells ECV304 were sensitive to AdhENDO-VEGI$_{151}$, and cell proliferation was significantly inhibited. In contrast, no inhibitory activities on HepG2 and L929 in vitro growth were observed following AdhENDO-VEGI$_{151}$ infection (Figure 3). Further analysis of variance showed there was a significant difference in viability between ECV304 cells and non-endothelial cells (HepG2 cells and L929 cells) ($F=13112.13, P=0.0001$). At different time points, there was a significant difference between the two groups ($F=72.75, P=0.0001$). There was no significant difference in viability between HepG2 cells and L929 cells neither for the hypothesis of no time effect ($F=7.17, P=0.0554$) nor at different time point ($F=1.74, P=0.2424$).

Inhibition of chick embryonic chorioallantoic membrane angiogenesis (×7)

Suppression of rabbit corneal neovascularization (×7), CNV was examined on day 21. A: AdLacZ control; B: AdhENDO-VEGI$_{151}$. 

Pan X et al. Effects of chimeric recombinant adenoviruses on antiangiogenesis 1411
Angiogenesis inhibition by AdhENDO-VEGI151 in CAM

Nine-day-old chick embryos were incubated with filter disks infected with AdhENDO-VEGI151, or AdLacZ. The effect of AdhENDO-VEGI151 on CAM angiogenesis was analyzed 3 d after incubation, by excising the membrane around the air sac and microscopy (Figure 4). At doses of 10-20 µL/disc at a titer of 1x10^12 TCID₅₀/L, there was a potent inhibition of angiogenesis of AdhENDO-VEGI151 on the tested CAMs (n=4/group). In contrast, AdLacZ failed to suppress angiogenesis in CAM. There was no evidence of toxicity in any chick embryos tested.

Vessel inhibition in inflammatory cornea of rabbits

After direct subconjunctival injection of recombinant adenoviruses, rabbit eyes were examined by a surgical microscope daily. A few small capillary buds that arose from engorged limbal arcades were observed. CNV increased gradually, peaked on d 12-14, and degenerated on day 15 after suture induction. So we chose d 7, 10, 13, or 16 as time points to determine the number and length of vessels, and the area of neovascularization. Analysis of the CNV area found that local application of AdhENDO-VEGI151 resulted in a significant suppression of CNV (Figure 5, Figure 6). Repeated measurement of two factors and multilevel analysis of variance showed there were significant differences between AdhENDO-VEGI151 group and AdlacZ group (F=1413.11, P=0.0001) for the hypothesis of no time effect. At different time points, there was a significant difference between the two groups (F=15517.87, P=0.0001).

Determination of intratumor microvessel density

The antiangiogenesis effect of fusion protein producing adenoviruses was evaluated in tumor model. Tumor microvessel density (MVD) was reduced by the production of hENDO-VEGI151 fusion gene. The MVD was decreased (30.75±3.31%) more significantly in treated mice than in control (50.25±8.65%) (F=17.72, P=0.0056).

AdhENDO-VEGI151 expression in inflammatory cornea of rabbits

The fusion gene expression in inflammatory cornea of rabbits was detected by immunohistochemistry. Corneal endothelium was stained brown in AdLacZ group, others were stained negative. Corneal endothelium and epithelium were stained brown in AdhENDO-VEGI151 group (Figure 7), and lasted for 21 d.

AdhENDO-VEGI151 inhibited growth of liver cancer

Twenty-one days after therapy, the mice were sacrificed. Compared with AdLacZ control group (4 075.9±1 849.9 mm³), the average tumor size of AdhENDO-VEGI151 group had confirmed regression (487.7±241.2 mm³) (F=14.80, P=0.0085) with an inhibition rate of 88.03%.

Immunohistochemical features in liver cancer of nude mice

When we examined the sections stained by rabbit polyclonal anti-endostatin by a light microscope, strongly positive staining of fusion molecules presented in all cases of animals treated with AdhENDO-VEGI151. The recombinant adenoviruses carrying chimeric gene could be expressed in liver cancer. Brown staining was mainly located on the membrane of liver cancer cells (Figure 8). There was no positive staining in tumor tissues of the control animals.

DISCUSSION

Endostatin and vascular endothelial growth inhibitor are
endogenous angiostatic molecules. Both of them are angiogenesis inhibitors that could suppress the growth of endothelial cells[29,30]. To achieve effectiveness, angiogenic therapy with endostatin or VEGI in tumor-bearing mice required prolonged administration and high doses of recombinant proteins[31,32]. Production of functional polypeptides has proven difficult, perhaps because of its physical properties or variations in the purification procedures in different laboratories[33,34]. In our laboratory (Department of Microbiology, Second Military Medical University, Shanghai, China) these two recombinant proteins were used respectively to treat tumor-bearing nude mice, but their bioactivities were not satisfactory. So we performed angiogenic gene therapy with adenoviral vectors. The results suggested recombinant adenosines AdhENDO-VEGI[35] could express fusion protein about 41 ku in ECV304, HepG2, L929 and 293 cells, and showed a specific inhibition on the proliferation of ECV304 cells, the inhibition rate reached 49% in 24 h and 86% in 144 h, respectively. But the AdhENDO-VEGI[35] showed no suppression on growth of HepG2 cells, VEGI belongs to the tumor necrosis factor (TNF) superfamily[39] and was constitutively expressed in endothelial cells. Since murine fibroblast cell line L929 was used to determine the bioactivity of TNF, we also used this cell line to test the bioactivity of AdhENDO-VEGI[35]. The results showed it had no suppression on growth of L929 cells, suggesting that fusion protein expressed by AdhENDO-VEGI[35] infection had no cytotoxicity to non-endothelial cells. Chick choroidal membrane assay showed that fusion protein expressed by AdhENDO-VEGI[35] infection could significantly inhibit angiogenesis, and form no vessel regions. Because CAM was formed during embryogenic period, it was difficult to distinguish new vessels from previously established vascular networks. On the other hand, inflammatory CNV assay could avoid any confusion between new vessels and previously existed vessels, and any vessels penetrating into the corneal stroma could be identified as newly formed, as the cornea was avascular. For CNV was the main reason for corneal opacification, and also the main risk factor of immunologic rejection in allogeneic corneal transplantation, we tried to use AdhENDO-VEGI[35] as a safe and effective agent to inhibit CNV. We used intrastromal sutures to induce inflammatory CNV in rabbits. Neovascularization began sprouting into the corneal stroma from the limbus to the site of sutures within a few days after direct subconjunctival injection. Since small capillary vessels subsided gradually 16 d after suture induction, we selected d 7, 10, 13, or 16 as time points to measure vessel length and clock hours of circumferential neovascularization. Analysis of CNV area found there were significant differences between AdhENDO-VEGI[35] group and AdlacZ group. Local application of AdhENDO-VEGI[35] led to significant suppression of CNV, the inhibition rate was 36%, 16%, 17%, or 13% in turn. Our results suggested that in order to sustain the angiogenesis inhibition, AdhENDO-VEGI[35] should be administrated every 7 d. Immunohistochemical staining showed that the positive reaction was prominent in corneal endothelium in AdhENDO-VEGI[35] group. These results suggested that the expression of recombinant adenosines was related with the site of injection. Positive staining in corneal endothelium was observed in two groups. This phenomenon might be caused by the endogenous endostatin expression of corneal endothelial cells. Compared with AdlacZ control group, the average tumor size of AdhENDO-VEGI[35] group was reduced with an inhibition rate of 88.03%. The gene of interest in adenosines could express in liver cancer. Since the fusion gene included IL-3 signal peptide coding sequence, the fusion protein might secrete out of the membrane of liver cancer cells. MVD was decreased more significantly in treated mice than that in control, the inhibition rate was 39%. These findings in combination with the results of cell assay suggested that the antitumor activity of AdhENDO-VEGI[35] was not due to a direct effect on tumor cells, interference with the development of tumor microvessel density was responsible for tumor regression. However, up to now, we do not know whether the combination is more potent or not. Comparison of the effectiveness of fusion molecules with individual molecules has been under investigation.

REFERENCES

1. Kleiman HK, Liu G. Gene therapy for antiangiogenesis. J Natl Cancer Inst 2000; 92: 965-967.
2. Tomaneke RJ, Schachter GC. Angiogenesis: new insights and therapeutic potential. Nat Rev 2006; 361: 126-135.
3. Kim CW, Lee HM, Lee TH, Kang C, Kleiman HK, Gho YS. Extracellular membrane vesicles from tumor cells promote angiogenesis via sphenoglymin. Cancer Res 2002; 62: 6312-6317.
4. Oehler MK, Bicknell R. The promise of anti-angiogenic cancer therapy. Br J Cancer 2000; 82: 749-752.
5. Lai CM, Brankov M, Zakrich T, Lai YK, Shen WY, Constable JJ, Kovesdi I, Rakoczy PE. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum Gene Ther 2001; 12: 1299-1310.
6. Lai CM, Spilsbury K, Brankov M, Zakrich T, Rakoczy PE. Inhibition of corneal neovascularization by recombinant adenovirus-mediated antisense VEGF RNA. Exp Eye Res 2002; 75: 625-634.
7. Ambati BK, Joussen AM, Ambati J, Moromizato Y, Guha C, Javaherian K, Gillies S, O’Reilly MS, Adams AD. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002; 120: 1063-1068.
8. Hanaj H, Dhanabal M, Karumanchi SA, Albanese C, Waterman M, Chan B, Ramchandran R, Pestel R, Sukhatme VP. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 2002; 277: 16464-16469.
9. Zhang M, Wang L, Wang HX, Pan X, Pan W, Qi ZT. Effect of N-terminal deletion on biological activity of vascular endothelial cell growth inhibitor. Shengwu Huaxue Y u Shengwu Wuli Xuebao 2003; 35: 133-137.
10. Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY. Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth factor in vivo. Circ Res 2003; 89: 1161-1167.
11. Tanaka T, Cao Y, Folkman J, Fine HA. Viral vector-targeted antiangiogenic gene therapy utilizing an angiotatin complementary DNA. Cancer Res 1998; 58: 3362-3369.
12. Hample B, Tanaka T, Albert PS, Lee J, Ferrari N, Fine HA. Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Hum Gene Ther 2001; 12: 1713-1729.
13. Nguyen JT. Adeno-associated virus and other potential vectors for angiostatin and endostatin gene therapy. Adv Exp Med Biol 2000; 465: 457-466.
14. Nguyen JT, Wu P, Clouse ME, Hlakty L, Terwilliger EF. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antiangiogenesis strategy. Cancer Res 1998; 58: 5673-5677.
15. Cao GW, Qi ZT, Pan X, Zhang XQ, Miao XH, Feng Y, Lu XH, Kuriyama S, Du P. Gene therapy for human colorectal carcinoma using human CEAM promoter controlled bacterial ADP-ribosylating toxin genes human CEAM, PEA & GTA gene transfer. World J Gastroenterol 1998; 4: 389-391.
16. Li Z, Pan X, Pan W, Cao GS, Wen ZZ, Fang GE, Qi ZT, BI JW, Hua J. Packaging and identification of recombinant adenovirus carrying endostatin-soluble vascular endothelial growth factor inhibitor gene. Shijie Huan Xiu Aoluo Zazhi 2003; 11: 741-744.
17. Pan X, Li Z, Zhang M, Wang Y, Pan W, Qi ZT. Therapeutic effect of endostatin-vascular endothelial growth factor inhibitor recombinant adenosines on gastric carcinoma in nude mice. Shijie Huan Xiu Aoluo Zazhi 2003; 11: 1282-1285.
18. Noberg-Hofmann P, Ullman N, Giroux D, Aguilar-Cordova E. Sensitivity and reproducibility in adenosene infections titer determination. Nat Med 1997; 3: 808-811.
19. Michie J, Akudu J, Binder A, Van Rensburg CE, Bohm L.
Flow cytometric evaluation of apoptosis and cell viability as a criterion of anti-tumour drug toxicity. Anticancer Res 2003; 23: 2675-2679

20 Zhao CS, Zhang L, Shen YP. A preventive and therapeutic study of experimental corneal neovascularization. Tongji Yike Daxue Xuebao 1996; 25: 399-401

21 Cao Y, Linden P, Farnebo J, Cao R, Eriksson A, Kumar V, Qi JH, Claesson Welsh L, Ailtako K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A 1998; 95: 14389-14394

22 Saita N, Fujiwara N, Yano I, Soejima K, Kobayashi K. Trehalose 6,6'-dimycolate (cord factor) of Mycobacterium tuberculosis induces corneal angiogenesis in rats. Infect Immun 2000; 68: 5991-5997

23 Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP. Inhibition of angiogenesis by interleukin 4. J Exp Med 1998; 188: 1039-1046

24 Amin MA, Volpert OV, Woods JM, Kumar P, Harlow LA, Koch AE. Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase. Circ Res 2003; 93: 321-329

25 Seo K, Choi J, Park M, Rhee C. Angiogenesis effects of nerve growth factor (NGF) on rat corneas. J Vet Sci 2001; 2: 125-130

26 Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, Li LY. A novel secreted splice variant of vascular endothelial cell growth inhibitor. FASEB J 2002; 16: 742-744

27 NorJE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, Polverini PJ. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001; 61: 2183-2188

28 Olewnickz S, Chosia M, Kwas A, Kram A, Domagala W. Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol J Pathol 2002; 53: 183-188

29 Wang L, Pan W, Zhu FL, Jiao BH, Lou YH, Xiao Y, Qi ZT. Cloning, expression and biological activity of VEGI(151), a novel vascular endothelial cell growth inhibitor. Shengwu xue Yu Shengwu Wuli Xuebao 2000; 32: 485-489

30 Cao MM, Pan W, Chen QL, Ma ZC, Ni ZJ, Wu XL, Wu WB, Pan X, Cao GW, Qi ZT. Construction of the eukaryotic expression vector expressing the fusion protein of human endostatin protein and IL-1, signal peptide. Shijie Huaren Xiaohua Zazhi 2003; 9: 43-46

31 O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasiisht G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285

32 Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, Ni J, Yu GL, Li LY. Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. Int J Cancer 1999; 82: 131-136

33 Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP. Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999; 258: 345-352

34 Ding I, Sun JZ, Fenton B, Liu WM, Kimesely P, Okunieff P, Min W. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCA-4 murine mammary carcinomas. Cancer Res 2001; 61: 526-531

35 Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R, Yu GL. VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. FASEB J 1999; 13: 181-189